Interpace Biosciences Inc EBIT margin
Was ist das EBIT margin von Interpace Biosciences Inc?
EBIT margin von Interpace Biosciences Inc ist -1.56%
Was ist die Definition von EBIT margin?
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
EBIT margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Interpace Biosciences Inc
Was macht Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Unternehmen mit ebit margin ähnlich Interpace Biosciences Inc
- DSP hat EBIT margin von -1.61%
- China XD Plastics Co Ltd hat EBIT margin von -1.60%
- Hinduja Ventures hat EBIT margin von -1.58%
- Hudson Global Inc hat EBIT margin von -1.58%
- Zenith Exports hat EBIT margin von -1.58%
- Century Enka hat EBIT margin von -1.57%
- Interpace Biosciences Inc hat EBIT margin von -1.56%
- Douyu International Ltd hat EBIT margin von -1.55%
- Orient Press hat EBIT margin von -1.55%
- Cato hat EBIT margin von -1.54%
- Softing AG hat EBIT margin von -1.53%
- Yunhong CTI Ltd hat EBIT margin von -1.52%
- CareRx hat EBIT margin von -1.52%